Stock MYX MAYNE PHARMA GROUP LIMITED
Add to a list
To use this feature you must be a member
Log inSign up

Company Mayne Pharma Group Limited

Equities

MYX

AU000000MYX0

Pharmaceuticals

Delayed Australian S.E.
Other stock markets
 09:32:30 2024-05-28 pm EDT 		5-day change 1st Jan Change
5.11 AUD 0.00% Intraday chart for Mayne Pharma Group Limited -4.12% -16.75%
May. 24 Mayne Pharma Reiterates H2 FY24 Outlook in Wake of Change Healthcare Cyberattack MT
May. 10 Mayne Pharma Group's Nextstellis Oral Contraceptive Receives Two Additional US Patents MT

Business Summary

Mayne Pharma Group Limited is an Australia-based specialty pharmaceutical company focused on commercializing novel pharmaceuticals. The Company also provides contract development and manufacturing services to clients worldwide. The Company’s segments include Women’s Health, Dermatology, and International. The Women’s Health segment distributes women’s health branded products in the United States. This segment includes NEXTSTELLIS, ANNOVERA, BIJUVA, IMVEXXY and branded pre-natal vitamins. The Dermatology segment distributes established dermatology products in the United States. The International segment is engaged in the manufacture and sale of branded and generic pharmaceutical products globally and the provision of contract development and manufacturing services to third party customers. The Company's products include ACTIKERALL Solution, ASTRIX Capsules and Tablets, MAGNOPLASM Paste and SPLINTEX Splinter Removal Gel, and ANNOVERA Vaginal Ring, among others.

Number of employees: 967

Sales per Business

AUD in Million2022Weight2023Weight Delta
International
35.2 %
54 12.8 % 65 35.2 % +19.01%
Branded Products Division
33.7 %
11 2.5 % 62 33.7 % +485.69%
Portfolio Products Division
31.0 %
269 63.3 % 57 31.0 % -78.82%

Sales per region

AUD in Million2022Weight2023Weight Delta
United States
67.8 %
371 87.3 % 124 67.8 % -66.44%
Australia and New Zealand
22.4 %
34 7.9 % 41 22.4 % +22.24%
Canada
5.4 %
9 2.1 % 10 5.4 % +9.62%
Asia
2.4 %
5 1.1 % 4 2.4 % -9.86%
Europe and Other
2.0 %
6 1.5 % 4 2.0 % -42.36%

Managers

Managers TitleAgeSince
Shawn O'Brien CEO
 Chief Executive Officer - 22-09-30
Aaron Gray DFI
 Director of Finance/CFO - 22-08-28
Keith Moore CTO
 Chief Tech/Sci/R&D Officer - 14-12-31
Gerard G. Nahum CTO
 Chief Tech/Sci/R&D Officer - -
Frank Casty CTO
 Chief Tech/Sci/R&D Officer - -
Craig Haskins IRC
 Investor Relations Contact - -
Erinn Nathaniel HRO
 Human Resources Officer - -
Kimberly Parker LAW
 General Counsel - -
Richard Moldin PRN
 Corporate Officer/Principal - -
Laura Loftus PRN
 Corporate Officer/Principal - 20-03-25

Members of the board

Members of the board TitleAgeSince
Frank Condella CHM
 Chairman 70 18-05-29
Patrick Blake BRD
 Director/Board Member 59 18-06-27
Shawn O'Brien CEO
 Chief Executive Officer - 22-09-30
Kathryn MacFarlane BRD
 Director/Board Member 58 22-01-31
Bruce Robinson BRD
 Director/Board Member 67 14-08-25
Anne Lockwood BRD
 Director/Board Member - Nov. 29
Ann Custin BRD
 Director/Board Member 64 22-03-22
David Petrie BRD
 Director/Board Member - 22-08-31

Share class

VoteQuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 81,245,827 57,414,136 ( 70.67 %) 0 70.67 %

Shareholders

NameEquities%Valuation
Viburnum Funds Pty Ltd.
7.556 %
6,428,268 7.556 % 29 M $
Bruce Mathieson
6.221 %
5,292,066 6.221 % 24 M $
Rubric Capital Management LP
5.121 %
4,356,426 5.121 % 20 M $
Lazard Asset Management Pacific Co.
4.985 %
4,240,774 4.985 % 19 M $
MITHRA PHARMACEUTICALS S.A.
4.963 %
4,221,815 4.963 % 19 M $
Gft 2 Co. Pty Ltd.
1.523 %
1,295,569 1.523 % 6 M $
Scott Richards
1.505 %
1,280,211 1.505 % 6 M $
Ivl Group Ltd.
0.9404 %
800,000 0.9404 % 4 M $
Vivnat (Curtin) Pty Ltd.
0.8816 %
750,000 0.8816 % 3 M $
Investors Mutual Ltd.
0.7781 %
662,000 0.7781 % 3 M $

Company contact information

Mayne Pharma Group Ltd.

1538 Main North Road Salisbury South

5106, Salisbury

+61 8 8209 2666

http://www.maynepharma.com
address Mayne Pharma Group Limited(MYX)

Sector

Healthcare
Pharmaceuticals & Medical Research
Pharmaceuticals
Pharmaceuticals
Generic Pharmaceuticals

Sales per Business

Sales per region

Ratings for Mayne Pharma Group Limited

Trading Rating
Investor Rating
ESG Refinitiv
B-
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
5.11 AUD
Average target price
6.89 AUD
Spread / Average Target
+34.83%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Generic Pharmaceuticals

1st Jan change Capi.
MAYNE PHARMA GROUP LIMITED Stock Mayne Pharma Group Limited
-16.91% 279M
SUN PHARMACEUTICAL INDUSTRIES LTD. Stock Sun Pharmaceutical Industries Ltd.
+16.31% 42.32B
OTSUKA HOLDINGS CO., LTD. Stock Otsuka Holdings Co., Ltd.
+16.32% 21.29B
SANDOZ GROUP AG Stock Sandoz Group AG
+19.33% 15.29B
CIPLA LIMITED Stock Cipla Limited
+18.71% 14.36B
ZYDUS LIFESCIENCES LIMITED Stock Zydus Lifesciences Limited
+52.78% 12.81B
THE MEDICINES COMPANY Stock The Medicines Company
-0.05% 6.79B
ONO PHARMACEUTICAL CO., LTD. Stock Ono Pharmaceutical Co., Ltd.
-12.24% 6.58B
STADA ARZNEIMITTEL Stock STADA Arzneimittel
-8.87% 5.73B
ASPEN PHARMACARE HOLDINGS LIMITED Stock Aspen Pharmacare Holdings Limited
+14.28% 5.51B
Generic Pharmaceuticals
  1. Stock Market
  2. Equities
  3. MYX Stock
  4. Company Mayne Pharma Group Limited